Kurt de Vlam

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

Christian Antoni, Gerald G. Krueger, Kurt de Vlam et al. · Annals of the Rheumatic Diseases · 2005 · 716 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Josef S Smolen, Monika Schöls, Jürgen Braun et al. · Annals of the Rheumatic Diseases · 2017 · 676 citations · Full text

Medicine, Dermatology, Internal Medicine +14

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

Laure Gossec, Josef S Smolen, C. Gaujoux-Viala et al. · Annals of the Rheumatic Diseases · 2011 · 447 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative

Laure Gossec, Maarten de Wit, Uta Kiltz et al. · Annals of the Rheumatic Diseases · 2014 · 421 citations · Full text

Medicine, Clinical Sciences, Health Assessment +16

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

Mark C. Genovese, Kenneth Kalunian, Jacques‐Eric Gottenberg et al. · JAMA · 2019 · 327 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17